GLP-1 medications are changing what some consumers need from food. For manufacturers, the response goes beyond smaller portions. Companies are developing products that combine protein, fiber, and essential nutrients in formats designed around reduced appetites, creating a different set of priorities for food R&D teams.
.png)
The shift is already visible in frozen meals, cultured dairy drinks, and nutritional shakes. Nestlé’s Vital Pursuit brand was developed for GLP-1 users and consumers managing their weight. Danone introduced Oikos Fusion with a nutrient blend aimed at supporting muscle health during weight loss. Nestlé Health Science’s BOOST Advanced combines protein, prebiotic fiber, and B vitamins in a nutritional shake positioned for adults on a GLP-1 weight-loss journey.
These launches illustrate a broader development challenge: how to deliver a targeted nutritional profile while preserving the qualities that make a product enjoyable and practical to consume.
A different formulation brief: More nutrition in a manageable serving
For food manufacturers responding to GLP-1 use, portion size and nutritional composition are increasingly connected. Making a product smaller does not necessarily make it better suited to someone eating less. The formulation also needs to reflect the nutritional purpose of that serving. Nestlé made this relationship explicit when it introduced Vital Pursuit, describing the range as high in protein, a good source of fiber, and “portion-aligned” to a weight-loss medication user’s appetite.
That creates a more demanding brief than reducing calories alone. Developers may need to increase protein or fiber, adjust sweetness, and incorporate selected vitamins and minerals while keeping the product appealing in a smaller format. Ingredient suppliers report that these changes can affect taste, texture, mouthfeel, and stability, making GLP-1-oriented development a balancing exercise rather than a straightforward fortification project.
Several companies show how that brief is taking shape.
Nestlé: Designing frozen meals around portion size and nutrient delivery
Nestlé introduced Vital Pursuit in 2024 as a new food brand intended for GLP-1 users and consumers focused on weight management. By its nationwide launch in September, the portfolio included 14 frozen meals, each providing at least 20 grams of protein. Products included bowls, sandwich melts, pizzas, and air-fryer meals.
The range illustrates how manufacturers can rethink familiar foods rather than create an entirely unfamiliar eating experience. One example is the Vermont White Cheddar Mac & Broccoli Bowl with Cavatappi Protein Pasta, which incorporates protein pasta into a recognizable meal format. Other products combine proteins, vegetables, and whole grains, with essential nutrients varying by recipe.
The R&D significance is the relationship between the nutritional target and the finished eating experience. A protein-enriched pasta bowl still needs to work as a pasta dish. Its nutritional profile is only one part of the development brief; texture, flavor, preparation, and portion size remain part of the product’s appeal.
Vital Pursuit is best described as GLP-1-driven new product development, not evidence that Nestlé reformulated an existing frozen-meal range. That distinction matters when assessing how companies are responding to the market.
BOOST: Extending nutritional beverages for GLP-1-related needs
Nestlé Health Science’s BOOST Advanced Nutritional Shake offers a third example. The company describes the product as supporting the nutritional needs of adults on a GLP-1 weight-loss journey. Each serving provides 35 grams of protein, 4 grams of prebiotic fiber, and eight essential B vitamins.
Here, the response sits within an established nutritional beverage brand. The product combines multiple nutritional components in a convenient format, showing how companies can extend existing categories to address a more specific consumer need.
This is a useful distinction for R&D strategy. A manufacturer may develop an entirely new brand, create a new formulation within an established brand, or assess whether an existing product already meets the intended nutritional brief. Those routes require different development decisions, even when they respond to the same market trend.
Conagra: A reminder that a new label does not mean a new formula
Not every GLP-1-related product announcement represents formulation work.
In December 2024, Conagra announced that 26 Healthy Choice products would begin carrying an “On Track” badge in January 2025. The badge identified meals the company described as high in protein, low in calories, and a good source of fiber, making them “GLP-1 friendly.” Conagra explicitly stated that it had not changed the meals themselves.
This example belongs in the discussion precisely because it is not reformulation. It demonstrates another response: identifying products already in the portfolio and helping consumers find them.
For manufacturers, the first question is therefore not always “How should we change this recipe?” It may be “Which existing products already meet the brief, and where are the genuine gaps?” Conagra’s initiative shows why portfolio assessment should be kept distinct from ingredient changes and new product development.
Why GLP-1-oriented reformulation is a connected R&D challenge
The emerging product brief brings together requirements that can pull a formulation in different directions. More protein or fiber may support the intended nutritional positioning, but those changes can also alter taste, texture, sweetness, mouthfeel, and stability. Cargill, ADM, and Synergy Flavours have described the need to consider nutrition, portion size, sensory qualities, and functionality together when developing for GLP-1 users.
For an R&D team, this suggests a testing approach that evaluates the whole product rather than optimizing one nutritional measure in isolation. A practical development brief should connect:
- Nutritional targets to the intended serving size.
- Ingredient choices and inclusion levels to sensory and stability results.
- Formula versions to preparation or processing conditions.
- Finished-product performance to the criteria used to select the final recipe.
These are useful questions to carry through development, whether the project involves modifying an existing formula or creating a new product. They also make the distinction between those routes more visible: an unchanged recipe, a protein-enriched variant, and a purpose-built nutritional drink should not all be recorded or discussed as the same kind of innovation.
What this means for food manufacturers
The GLP-1 response is not one uniform reformulation trend. Nestlé’s Vital Pursuit illustrates a new brand built around portion-aligned nutrition. Oikos Fusion and BOOST Advanced show targeted product development within established brands. Healthy Choice demonstrates how an existing portfolio can be repositioned without changing its formulas.
For food R&D teams, the opportunity is to turn that market signal into a precise development brief. Which nutritional requirements need to change? What serving format makes sense? Which existing formulas offer a useful starting point? And what evidence will show that the finished product meets its nutritional, sensory, and technical objectives?
Those questions provide a stronger foundation for product development than treating “GLP-1-friendly” as a formulation specification in its own right.
.png)
.png)
